Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear
This article was originally published in The Pink Sheet Daily
CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.
You may also be interested in...
Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.
The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo in clinical trials required under a ‘coverage with evidence development’ determination as a major improvement in its recent guidance for CED.
In comments on CMS’ recent draft guidance on Medicare coverage with evidence development, Onyx Pharmaceuticals recommends that cutting edge therapies with postmarketing commitments like its cancer drug Kyprolis should be exempted, and Amyvid marketer Lilly says CED is not appropriate for radiopharmaceuticals.